4:56 PM
 | 
Jun 13, 2011
 |  BC Extra  |  Clinical News

Edison reports Phase II data in Friedreich's ataxia

Edison Pharmaceuticals Inc. (San Jose, Calif.) said EPI-A0001 missed the primary endpoint in a Phase IIa trial to treat...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >